PREVADDUCT
DEAD

Serial Number

88912457

Owner

Adduct Pharmaceutical, Inc.

Attorney

Katherine Sullivan

Filing Date

May 12, 2020

Add to watchlist:

No watchlists yet
View on USPTO

PREVADDUCT Trademark

Serial Number: 88912457

PREVADDUCT is a trademark filed by Adduct Pharmaceutical, Inc. on May 12, 2020. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

Adduct Pharmaceutical, Inc. (2 trademarks)

2711 South Loop Drive, Suite 4400
Ames, IA 50010

Entity Type: 03

Trademark Details

Filing Date

May 12, 2020

Registration Date

Not Registered

Published for Opposition

September 15, 2020

Goods & Services

Dietary and nutritional supplements; Digestives for pharmaceutical purposes; Pharmaceutical products for treating respiratory diseases and asthma; Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting metabolism; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents for epidermis; Pharmaceutical anti-allergic preparations and substances; Pharmaceutical preparation for skin care; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations for the prevention of inflammation; Pharmaceutical preparations for the prevention of inflammatory diseases; Pharmaceutical preparations for the treatment and prevention of oxidative damage; Pharmaceutical preparations for the treatment and prevention of chronic inflammation; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of hormonal disorders; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of musculo-skeletal disorders; Pharmaceutical preparations for the treatment of chronic inflammation; Pharmaceutical preparations for the treatment of oxidative damage; Pharmaceutical preparations for the treatment of isoketal activity diseases and conditions; Pharmaceutical preparations for the treatment of musculoskeletal, cardiovascular, cardiopulmonary, and immune system related diseases and disorders; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for treating asthma; Pharmaceutical preparations for treating chemical imbalances; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for inflammation; Pharmaceutical preparations, namely, anticoagulants; Pharmaceutical preparations, namely, antidepressants; Pharmaceutical preparations, namely, antivirals; Pharmaceutical products and preparations against dry skin caused by pregnancy; Pharmaceutical products and preparations for pregnancy blemishes; Pharmaceutical products for ophthalmological use; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for the treatment of cancer; Pharmaceutical products for the treatment of joint disease; Pharmaceutical products for treating respiratory diseases; Anti-inflammatory preparations; Chemical preparations for pharmaceutical or medical purposes, namely, for oxidative damage, isoketal activity and chronic inflammation; Chemical preparations for pharmaceutical or medical purposes, namely, for diseases resulting from oxidative damage, isoketal activity or inflammation; Food supplements, namely, anti-oxidants; Medical preparations for the treatment of oxidative damage, isoketal activity and chronic inflammation; Medicinal preparations for inflammation; Pharmaceutical products and preparations to prevent swelling in the legs; Preparation for the relief of pain

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Dec 18, 2023 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Dec 18, 2023 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 12, 2023 EXRA
SOU EXTENSION 5 GRANTED
May 11, 2023 EX5G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
May 11, 2023 AITU
SOU EXTENSION 5 FILED
May 7, 2023 EXT5
SOU TEAS EXTENSION RECEIVED
May 7, 2023 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 12, 2022 EXRA
SOU EXTENSION 4 GRANTED
Nov 10, 2022 EX4G
SOU EXTENSION 4 FILED
Nov 10, 2022 EXT4
SOU TEAS EXTENSION RECEIVED
Nov 10, 2022 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 10, 2022 EXRA
SOU EXTENSION 3 GRANTED
May 8, 2022 EX3G
SOU EXTENSION 3 FILED
May 8, 2022 EXT3
SOU TEAS EXTENSION RECEIVED
May 8, 2022 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 9, 2021 EXRA
SOU EXTENSION 2 GRANTED
Nov 5, 2021 EX2G
SOU EXTENSION 2 FILED
Nov 5, 2021 EXT2
SOU TEAS EXTENSION RECEIVED
Nov 5, 2021 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 12, 2021 EXRA
SOU EXTENSION 1 GRANTED
May 10, 2021 EX1G
SOU EXTENSION 1 FILED
May 10, 2021 EXT1
SOU TEAS EXTENSION RECEIVED
May 10, 2021 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Nov 10, 2020 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 15, 2020 NPUB
PUBLISHED FOR OPPOSITION
Sep 15, 2020 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 26, 2020 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 11, 2020 CNSA
ASSIGNED TO EXAMINER
Aug 9, 2020 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 26, 2020 NWOS
NEW APPLICATION ENTERED
May 15, 2020 NWAP